Federal grants to Kovina Therapeutics Inc
Kovina Therapeutics Inc in Indianapolis, Indiana received $2.9 million in federal grants from fiscal 2021 to 2025, across 4 awards. Its largest program was Cancer Cause and Prevention Research, with $2.3 million. In fiscal 2025 more was taken back from its awards than added, a net -$2,849.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$2.9 million
- Awards4
- Awarded in FY 2025-$2,849
- Largest award$2.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 0 | $0 |
| FY 2022 | 3 | $995,282 |
| FY 2023 | 1 | $909,657 |
| FY 2024 | 1 | $1.0 million |
| FY 2025 | 0 | -$2,849 |
Programs that fund Kovina Therapeutics Inc
| Program | Awards | Amount |
|---|---|---|
| Cancer Cause and Prevention Research | 2 | $2.3 million |
| Allergy and Infectious Diseases Research | 1 | $298,527 |
| Oral Diseases and Disorders Research | 1 | $272,917 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 4 | $2.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| From academia to business: development of novel therapeutics against hpv-associated cancer - abstract “high-risk” human papillomavirus (HPV) types such as 16 (HPV-16) are identified in the majority of hpv-associated pre-malignant and malignant pathologies of cervical, anogenital, and oropharyngeal e | Cancer Cause and Prevention Research | April 27, 2023 | $2.0 million |
| From academia to business: development of novel therapeutics against hpv-associated cancer - abstract “high-risk” human papillomavirus (HPV) types such as 16 (HPV-16) are identified in the majority of hpv- associated pre-malignant and malignant pathologies of cervical, anogenital, and oropharyngeal | Cancer Cause and Prevention Research | February 25, 2022 | $369,115 |
| Small molecule E6 inhibitors to treat dysplasia caused by hpv infections - human papillomaviruses (HPV) cause exceedingly common infections of cutaneous and mucosal epithelia. Infection with specific “high risk” hpv genotypes can progress to pre- malignant lesions called dysplasias, which over a per | Allergy and Infectious Diseases Research | June 30, 2022 | $298,527 |
| Small molecule E6 inhibitors to treat oropharyngeal cancers caused by hpv infections - oncogenic human papillomaviruses (HPV) such as hpv type 16 are the etiologic agent of 50-70% of cancers of the oropharynx. In the USA, the incidence of hpv-associated oropharyngeal cancers is increasing. This is p | Oral Diseases and Disorders Research | August 11, 2022 | $272,917 |
Questions people ask
How much federal grant money does Kovina Therapeutics Inc get?
$2.9 million in 4 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Kovina Therapeutics Inc the most?
The Department of Health and Human Services, with $2.9 million in 4 awards.
What is Kovina Therapeutics Inc's largest federal grant?
$2.0 million under Cancer Cause and Prevention Research, with its first action in the period on April 27, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Kovina Therapeutics Inc?
Its largest are Cancer Cause and Prevention Research, Allergy and Infectious Diseases Research and Oral Diseases and Disorders Research.
Other grant recipients in Indianapolis
- Indiana Family and Social Serv
- Department of Education Indiana
- Indiana Department of Transportation
- Department of Child Services
- Indiana Department of Health
- State of Indiana
- Trustees of Indiana University
- Indiana Housing and Community Development Authority
Largest federal grant recipients in Indiana · Federal grants in Indiana